Company overview

Allergy Therapeutics is an AIM-listed multinational pharmaceutical company focused on the diagnosis, treatment and prevention of allergic conditions, with a special emphasis on allergy vaccination. The company is a combination of a revenue based business with a sales base of £60m per annum and a “Biotech” business with tremendous potential in the USA. With 480 staff and representation in the UK, USA, Germany, Austria, Spain, Italy, Netherlands and Austria, Allergy Therapeutics is a leader in its field with a 5 year plan to expand rapidly, particularly within the emerging US market.

The process

To support this vision, Directorbank was approached to source a Non-Executive Director to augment the Board of Directors. Key responsibilities of the role would involve providing specific knowledge on current drug trialling and regulatory regime in the US and advice regarding entry into and development of US markets. The ideal candidate profile would encompass:

A proven executive with significant experience of the Pharma sector in the US and substantial knowledge of the US drug trialling and regulatory regime (the FDA)

A track record in R&D, clinical development, clinical trials and registering new products, particularly within the US market. Experience of developing vaccines or advanced allergy treatments would be beneficial

Board or senior management experience in a mid cap company or plc

A strong network of significant people and key opinion leaders, including doctors and pharmacists, within the US

After a thorough search process incorporating a robust mapping exercise of the pharmaceutical sector, more than 60 relevant individuals were identified for assessment. Six candidates were put forward for interview and Dr Tunde Otulana was successfully appointed to the role.

The result

Tunde brings more than 20 years’ pharmaceutical industry knowledge and significant executive level experience in clinical development and medical affairs roles. He currently serves as Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals (New Jersey, US) where he has responsibility for all global medical functions, and has previously worked for Boehringer Ingelheim Pharmaceutical Inc (Connecticut, US) as Senior Vice President, Clinical Development and Medical Affairs. He has previously spent over six years working at the US Food and Drug Administration (FDA) as a Medical Officer and Medical Team Leader in the Division of Pulmonary-Allergy Drug Products.